Splisense

SpliSense is a clinical-stage biotechnology company focused on developing transformative RNA-based treatments for unmet needs in diverse pulmonary diseases. Utilizing clinically validated Antisense Oligonucleotide (ASO) technology, SpliSense delivers its treatments non-invasively by inhalation directly to the lungs. The company is engaged in various stages of drug development, from discovery to Investigational New Drug (IND) applications. SpliSense primarily serves patients suffering from severe pulmonary conditions such as Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The company's business model revolves around the research, development, and commercialization of its innovative therapies. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved treatments.

Keywords: RNA-based treatments, pulmonary diseases, Antisense Oligonucleotide, inhalation delivery, clinical-stage, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, biotechnology, drug development, non-invasive therapy.